Company profile TRDA
There is not enough data for Entrada Therapeutics - biotechnology to provide analysis
There is not enough data for Entrada Therapeutics - biotechnology to provide correlation calculation
There is not enough data for Entrada Therapeutics - biotechnology to provide analysis
There is not enough data for ENTR-601-44 preclinical trial to provide analysis
There is not enough data for ENTR-601-44 preclinical trial to provide correlation calculation
There is not enough data for ENTR-601-44 preclinical trial to provide analysis
There is not enough data for ENTR-601-45 preclinical trial to provide analysis
There is not enough data for ENTR-601-45 preclinical trial to provide correlation calculation
There is not enough data for ENTR-601-45 preclinical trial to provide analysis
After 34 days of this quarter the interest is at 67.0. Based on that we can calculate that during remaining 58 days it will total up to 181.0. Duchenne muscular dystrophy treatment expected interest is significantly lower compared to same quarter last year (-45.2%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 283 |
| 2019 | 564 99.3% QoQ | 347 -38.5% QoQ | 256 -26.2% QoQ | 398 40.6% YoY 55.5% QoQ |
| 2020 | 295 -47.7% YoY -25.9% QoQ | 181 -47.8% YoY -38.6% QoQ | 212 -17.2% YoY 17.1% QoQ | 193 -51.5% YoY -9.0% QoQ |
| 2021 | 223 -24.4% YoY 15.5% QoQ | 191 5.5% YoY -14.3% QoQ | 155 -26.9% YoY -18.8% QoQ | 158 -18.1% YoY 1.9% QoQ |
| 2022 | 211 -5.4% YoY 33.5% QoQ | 288 50.8% YoY 36.5% QoQ | 62 -60.0% YoY -78.5% QoQ | 330 108.9% YoY 432.3% QoQ |
| 2023 | 278 31.8% YoY -15.8% QoQ | 267 -7.3% YoY -4.0% QoQ | 255 311.3% YoY -4.5% QoQ | 67 -79.7% YoY -73.7% QoQ |
The average 5 years interest of Duchenne muscular dystrophy treatment was 19.98 per week. The last year interest of Duchenne muscular dystrophy treatment compared to the last 5 years has changed by 6.96%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -29.12%.
There is not enough data for myotonic dystrophy type 1 treatment to provide analysis
There is not enough data for myotonic dystrophy type 1 treatment to provide correlation calculation
There is not enough data for myotonic dystrophy type 1 treatment to provide analysis
There is not enough data for ENTR-501 preclinical trial to provide analysis
There is not enough data for ENTR-501 preclinical trial to provide correlation calculation
There is not enough data for ENTR-501 preclinical trial to provide analysis
There is not enough data for mitochondrial neurogastrointestinal encephalomyopathy treatment to provide analysis
There is not enough data for mitochondrial neurogastrointestinal encephalomyopathy treatment to provide correlation calculation
There is not enough data for mitochondrial neurogastrointestinal encephalomyopathy treatment to provide analysis
There is not enough data for ENTR-701 preclinical trial to provide analysis
There is not enough data for ENTR-701 preclinical trial to provide correlation calculation
There is not enough data for ENTR-701 preclinical trial to provide analysis
There is not enough data for myotonic dystrophy type 1 treatment to provide analysis
There is not enough data for myotonic dystrophy type 1 treatment to provide correlation calculation
There is not enough data for myotonic dystrophy type 1 treatment to provide analysis
After 39 days of this quarter the interest is at 332.0. Based on that we can calculate that during remaining 52 days it will total up to 775.0. biotechnology company expected interest is significantly higher compared to previous quarter (+44.3%) and same quarter last year (+51.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 181 | 308 70.2% QoQ | 187 -39.3% QoQ | 245 31.0% QoQ |
| 2020 | 511 182.3% YoY 108.6% QoQ | 479 55.5% YoY -6.3% QoQ | 349 86.6% YoY -27.1% QoQ | 413 68.6% YoY 18.3% QoQ |
| 2021 | 586 14.7% YoY 41.9% QoQ | 309 -35.5% YoY -47.3% QoQ | 361 3.4% YoY 16.8% QoQ | 303 -26.6% YoY -16.1% QoQ |
| 2022 | 419 -28.5% YoY 38.3% QoQ | 525 69.9% YoY 25.3% QoQ | 403 11.6% YoY -23.2% QoQ | 336 10.9% YoY -16.6% QoQ |
| 2023 | 511 22.0% YoY 52.1% QoQ | 424 -19.2% YoY -17.0% QoQ | 371 -7.9% YoY -12.5% QoQ | 537 59.8% YoY 44.7% QoQ |
| 2024 | 332 -35.0% YoY -38.2% QoQ | - | - | - |
The average 5 years interest of biotechnology company was 31.0 per week. The last year interest of biotechnology company compared to the last 5 years has changed by 20.42%. The interest for biotechnology company is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 80.08%.
There is not enough data for endosomal escape vehicle therapeutics to provide analysis
There is not enough data for endosomal escape vehicle therapeutics to provide correlation calculation
There is not enough data for endosomal escape vehicle therapeutics to provide analysis
There is not enough data for oligonucleotide-based programs to provide analysis
There is not enough data for oligonucleotide-based programs to provide correlation calculation
There is not enough data for oligonucleotide-based programs to provide analysis
There is not enough data for antibody-based programs to provide analysis
There is not enough data for antibody-based programs to provide correlation calculation
There is not enough data for antibody-based programs to provide analysis
There is not enough data for enzyme-based programs to provide analysis
There is not enough data for enzyme-based programs to provide correlation calculation
There is not enough data for enzyme-based programs to provide analysis